Blood-brain transfer of Pittsburgh compound B in humans

Albert Gjedde, Joel Aanerud, Hans Braendgaard, Anders B. Rodell

Research output: Contribution to journalArticle

Abstract

In the labeled form, the Pittsburgh compound B (2-(4'-{N-methyl-[11C]}methyl-aminophenyl)-6-hydroxy-benzothiazole, [11C]PiB), is used as a biomarker for positron emission tomography (PET) of brain β-amyloid deposition in Alzheimer's disease (AD). The permeability of [11C]PiB in the blood-brain barrier is held to be high but the permeability-surface area product and extraction fractions in patients or healthy volunteers are not known. We used PET to determine the clearance associated with the unidrectional blood-brain transfer of [11C]PiB and the corresponding cerebral blood flow rates in frontal lobe, whole cerebral cortex, and cerebellum of patients with Alzheimer's disease and healthy volunteers. Regional cerebral blood flow rates differed significantly between the two groups. Thus, regional and whole-brain permeability-surface area products were identical, in agreement with the observation that numerically, but insignificantly, unidirectional blood-brain clearances are lower and extraction fractions higher in the patients. The evidence of unchanged permeability-surface area products in the patients implies that blood flow changes can be deduced from the unidirectional blood-brain clearances of [11C]PiB in the patients.

Original languageEnglish (US)
Article numberArticle 70
JournalFrontiers in Aging Neuroscience
Volume5
Issue numberNOV
DOIs
StatePublished - 2013

Fingerprint

Permeability
Cerebrovascular Circulation
Brain
Positron-Emission Tomography
Healthy Volunteers
Alzheimer Disease
Regional Blood Flow
Frontal Lobe
Blood-Brain Barrier
Amyloid
Cerebral Cortex
Cerebellum
Biomarkers
2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole

Keywords

  • Alzheimers disease
  • Blood-brain barrier
  • Cerebral blood flow measurement
  • Permeability-surface area product
  • Pittsburgh compound B

ASJC Scopus subject areas

  • Cognitive Neuroscience
  • Aging

Cite this

Gjedde, A., Aanerud, J., Braendgaard, H., & Rodell, A. B. (2013). Blood-brain transfer of Pittsburgh compound B in humans. Frontiers in Aging Neuroscience, 5(NOV), [Article 70]. https://doi.org/10.3389/fnagi.2013.00070

Blood-brain transfer of Pittsburgh compound B in humans. / Gjedde, Albert; Aanerud, Joel; Braendgaard, Hans; Rodell, Anders B.

In: Frontiers in Aging Neuroscience, Vol. 5, No. NOV, Article 70, 2013.

Research output: Contribution to journalArticle

Gjedde, A, Aanerud, J, Braendgaard, H & Rodell, AB 2013, 'Blood-brain transfer of Pittsburgh compound B in humans', Frontiers in Aging Neuroscience, vol. 5, no. NOV, Article 70. https://doi.org/10.3389/fnagi.2013.00070
Gjedde, Albert ; Aanerud, Joel ; Braendgaard, Hans ; Rodell, Anders B. / Blood-brain transfer of Pittsburgh compound B in humans. In: Frontiers in Aging Neuroscience. 2013 ; Vol. 5, No. NOV.
@article{875d26fd50234c7597dc6b7a70594796,
title = "Blood-brain transfer of Pittsburgh compound B in humans",
abstract = "In the labeled form, the Pittsburgh compound B (2-(4'-{N-methyl-[11C]}methyl-aminophenyl)-6-hydroxy-benzothiazole, [11C]PiB), is used as a biomarker for positron emission tomography (PET) of brain β-amyloid deposition in Alzheimer's disease (AD). The permeability of [11C]PiB in the blood-brain barrier is held to be high but the permeability-surface area product and extraction fractions in patients or healthy volunteers are not known. We used PET to determine the clearance associated with the unidrectional blood-brain transfer of [11C]PiB and the corresponding cerebral blood flow rates in frontal lobe, whole cerebral cortex, and cerebellum of patients with Alzheimer's disease and healthy volunteers. Regional cerebral blood flow rates differed significantly between the two groups. Thus, regional and whole-brain permeability-surface area products were identical, in agreement with the observation that numerically, but insignificantly, unidirectional blood-brain clearances are lower and extraction fractions higher in the patients. The evidence of unchanged permeability-surface area products in the patients implies that blood flow changes can be deduced from the unidirectional blood-brain clearances of [11C]PiB in the patients.",
keywords = "Alzheimers disease, Blood-brain barrier, Cerebral blood flow measurement, Permeability-surface area product, Pittsburgh compound B",
author = "Albert Gjedde and Joel Aanerud and Hans Braendgaard and Rodell, {Anders B.}",
year = "2013",
doi = "10.3389/fnagi.2013.00070",
language = "English (US)",
volume = "5",
journal = "Frontiers in Aging Neuroscience",
issn = "1663-4365",
publisher = "Frontiers Research Foundation",
number = "NOV",

}

TY - JOUR

T1 - Blood-brain transfer of Pittsburgh compound B in humans

AU - Gjedde, Albert

AU - Aanerud, Joel

AU - Braendgaard, Hans

AU - Rodell, Anders B.

PY - 2013

Y1 - 2013

N2 - In the labeled form, the Pittsburgh compound B (2-(4'-{N-methyl-[11C]}methyl-aminophenyl)-6-hydroxy-benzothiazole, [11C]PiB), is used as a biomarker for positron emission tomography (PET) of brain β-amyloid deposition in Alzheimer's disease (AD). The permeability of [11C]PiB in the blood-brain barrier is held to be high but the permeability-surface area product and extraction fractions in patients or healthy volunteers are not known. We used PET to determine the clearance associated with the unidrectional blood-brain transfer of [11C]PiB and the corresponding cerebral blood flow rates in frontal lobe, whole cerebral cortex, and cerebellum of patients with Alzheimer's disease and healthy volunteers. Regional cerebral blood flow rates differed significantly between the two groups. Thus, regional and whole-brain permeability-surface area products were identical, in agreement with the observation that numerically, but insignificantly, unidirectional blood-brain clearances are lower and extraction fractions higher in the patients. The evidence of unchanged permeability-surface area products in the patients implies that blood flow changes can be deduced from the unidirectional blood-brain clearances of [11C]PiB in the patients.

AB - In the labeled form, the Pittsburgh compound B (2-(4'-{N-methyl-[11C]}methyl-aminophenyl)-6-hydroxy-benzothiazole, [11C]PiB), is used as a biomarker for positron emission tomography (PET) of brain β-amyloid deposition in Alzheimer's disease (AD). The permeability of [11C]PiB in the blood-brain barrier is held to be high but the permeability-surface area product and extraction fractions in patients or healthy volunteers are not known. We used PET to determine the clearance associated with the unidrectional blood-brain transfer of [11C]PiB and the corresponding cerebral blood flow rates in frontal lobe, whole cerebral cortex, and cerebellum of patients with Alzheimer's disease and healthy volunteers. Regional cerebral blood flow rates differed significantly between the two groups. Thus, regional and whole-brain permeability-surface area products were identical, in agreement with the observation that numerically, but insignificantly, unidirectional blood-brain clearances are lower and extraction fractions higher in the patients. The evidence of unchanged permeability-surface area products in the patients implies that blood flow changes can be deduced from the unidirectional blood-brain clearances of [11C]PiB in the patients.

KW - Alzheimers disease

KW - Blood-brain barrier

KW - Cerebral blood flow measurement

KW - Permeability-surface area product

KW - Pittsburgh compound B

UR - http://www.scopus.com/inward/record.url?scp=84895825026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895825026&partnerID=8YFLogxK

U2 - 10.3389/fnagi.2013.00070

DO - 10.3389/fnagi.2013.00070

M3 - Article

VL - 5

JO - Frontiers in Aging Neuroscience

JF - Frontiers in Aging Neuroscience

SN - 1663-4365

IS - NOV

M1 - Article 70

ER -